CTi Biopharma Corp Valuation

CTi Biopharma Investor Information

About 83.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.54. CTi Biopharma Corp last dividend was issued on the 3rd of January 2017. The entity had 1:10 split on the 3rd of January 2017. Based on the key measurements obtained from CTi Biopharma's financial statements, CTi Biopharma Corp is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.

CTi Biopharma Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. CTi Biopharma has an asset utilization ratio of 42.84 percent. This indicates that the Company is making $0.43 for each dollar of assets. An increasing asset utilization means that CTi Biopharma Corp is more efficient with each dollar of assets it utilizes for everyday operations.

CTi Biopharma Ownership Allocation

CTi Biopharma holds a total of 131.88 Million outstanding shares. The majority of CTi Biopharma Corp outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in CTi Biopharma Corp to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in CTi Biopharma. Please pay attention to any change in the institutional holdings of CTi Biopharma Corp as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

CTi Biopharma Profitability Analysis

The company reported the previous year's revenue of 53.95 M. Net Loss for the year was (92.99 M) with profit before overhead, payroll, taxes, and interest of 50.43 M.

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.

Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

If you are still planning to invest in CTi Biopharma Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CTi Biopharma's history and understand the potential risks before investing.